You are here

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF
PostScript
Letter
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus
  1. Kenneth Cusi
  1. Correspondence to Dr Kenneth Cusi, Division of Endocrinology, Diabetes and Metabolism, University of Florida, 1600 SW Archer Road, Room H-2. Gainesville, FL 32610, USA; Kenneth.Cusi{at}medicine.ufl.edu

http://dx.doi.org/10.1136/gutjnl-2017-313958

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with great interest the recent comprehensive review by Rotman and Sanyal.1 I would just like to point out an error in table 1 (row 1), where the authors inadvertently state that pioglitazone has shown histological benefit only in secondary analyses and not been studied in patients with diabetes and nonalcoholic fatty liver disease (NAFLD). Benefit with the thiazolidinedione has been reported for the primary histological outcome in two randomised controlled trials (RCTs) in patients with prediabetes or type 2 diabetes mellitus (T2DM). This is most likely an oversight as in the …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles